Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong
· Delayed Price · Currency is HKD 3.890
-0.060 (-1.52%)
Apr 3, 2025, 4:08 PM HKT
Sino Biopharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | - | 2,332 | 2,544 | 14,608 | 2,771 | Upgrade
|
| Depreciation & Amortization | - | 1,004 | 967.54 | 922.74 | 1,637 | Upgrade
|
| Other Amortization | - | 70.05 | 79.45 | 129.82 | 87.21 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -62.69 | -3.47 | 4.28 | 0.59 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 19.4 | 492.1 | 13.64 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 13.72 | 449.08 | 420.04 | -443.44 | Upgrade
|
| Loss (Gain) on Equity Investments | - | 525.71 | 152.98 | -13,631 | 3.23 | Upgrade
|
| Stock-Based Compensation | - | 18.12 | 29.72 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | - | -12.26 | 3.93 | 1.62 | -3.08 | Upgrade
|
| Other Operating Activities | - | 2,316 | 1,655 | 2,757 | 997.86 | Upgrade
|
| Change in Accounts Receivable | - | -816.03 | -421.66 | -1,308 | -198.79 | Upgrade
|
| Change in Inventory | - | 135.32 | -391.1 | -57.48 | -221.45 | Upgrade
|
| Change in Accounts Payable | - | 284.3 | -55.8 | -257.84 | 206.5 | Upgrade
|
| Change in Unearned Revenue | - | -142.32 | 74.62 | 66.25 | 127.55 | Upgrade
|
| Change in Other Net Operating Assets | - | 108.21 | 598.34 | 1,218 | 347.52 | Upgrade
|
| Operating Cash Flow | - | 6,066 | 6,265 | 5,366 | 5,325 | Upgrade
|
| Operating Cash Flow Growth | - | -3.18% | 16.75% | 0.77% | 0.01% | Upgrade
|
| Capital Expenditures | - | -1,068 | -1,243 | -1,714 | -1,424 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 100.99 | 27.89 | 132.2 | 101.15 | Upgrade
|
| Cash Acquisitions | - | -1,157 | - | -798.75 | - | Upgrade
|
| Divestitures | - | 413.81 | -146.17 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -406.78 | -302.94 | -152.92 | -363.99 | Upgrade
|
| Investment in Securities | - | 568.91 | -3,703 | -4,391 | -6,542 | Upgrade
|
| Other Investing Activities | - | 790.43 | 1,297 | 4,408 | 383.13 | Upgrade
|
| Investing Cash Flow | - | -756.98 | -4,071 | -2,516 | -7,846 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 136.13 | - | Upgrade
|
| Long-Term Debt Issued | - | 12,194 | 9,753 | 1,270 | 7,150 | Upgrade
|
| Total Debt Issued | - | 12,194 | 9,753 | 1,406 | 7,150 | Upgrade
|
| Long-Term Debt Repaid | - | -13,948 | -8,790 | -2,908 | -1,809 | Upgrade
|
| Net Debt Issued (Repaid) | - | -1,754 | 962.99 | -1,501 | 5,340 | Upgrade
|
| Repurchase of Common Stock | - | -396.39 | -867.61 | -332.93 | -195.37 | Upgrade
|
| Common Dividends Paid | - | -632.67 | -1,268 | -938.49 | -1,187 | Upgrade
|
| Other Financing Activities | - | -3,766 | -2,014 | -452.37 | -1,725 | Upgrade
|
| Financing Cash Flow | - | -6,549 | -3,186 | -3,225 | 2,233 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 90.52 | 47.32 | -649.71 | 280.02 | Upgrade
|
| Net Cash Flow | - | -1,150 | -944.73 | -1,025 | -7.02 | Upgrade
|
| Free Cash Flow | - | 4,998 | 5,022 | 3,652 | 3,901 | Upgrade
|
| Free Cash Flow Growth | - | -0.48% | 37.50% | -6.38% | 0.67% | Upgrade
|
| Free Cash Flow Margin | - | 19.08% | 19.30% | 13.60% | 16.50% | Upgrade
|
| Free Cash Flow Per Share | - | 0.27 | 0.26 | 0.19 | 0.21 | Upgrade
|
| Cash Interest Paid | - | 480.83 | 339.52 | 179.62 | 215.31 | Upgrade
|
| Cash Income Tax Paid | - | 746.57 | 892.09 | 726.72 | 959.18 | Upgrade
|
| Levered Free Cash Flow | - | 3,006 | 2,991 | -196.74 | 3,669 | Upgrade
|
| Unlevered Free Cash Flow | - | 3,316 | 3,259 | -3.85 | 3,871 | Upgrade
|
| Change in Net Working Capital | -188.87 | -298.4 | -362.74 | 2,085 | -1,374 | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.